作者:Galina Lepesheva、Plamen Christov、Gary A. Sulikowski、Kwangho Kim
DOI:10.1016/j.tetlet.2017.09.070
日期:2017.11
azole-based CYP51 inhibitors is an active area of research across disciplines of biochemistry, pharmacology and infectious disease. Support of in vitro and in vivo studies require the development of robust asymmetric routes to single enantiomer products of this class of compounds. Herein, we describe a scalable and enantioselective synthesis to VNI and VFV, the two potent inhibitors of protozoan sterol
唑基CYP51抑制剂的研究和开发是跨生物化学,药理学和传染病学科的活跃研究领域。体外和体内研究的支持要求开发出鲁棒的不对称途径,以制备此类化合物的单个对映体产物。在这里,我们描述了对VNI和VFV的可扩展和对映选择性合成,VNI和VFV是原生动物固醇14α-脱甲基酶(CYP51)的两种有效抑制剂,目前正考虑用于Chagas病的临床试验。关键的转化是雅各布森水解动力学拆分(HKR)反应。合成路线的实用性通过制备> 25 g的VNI和VFV单一对映体来说明。